Anthony Reiman
Overview
Explore the profile of Anthony Reiman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner C, et al.
Cancer Med
. 2024 Nov;
13(21):e70332.
PMID: 39499045
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods: We explored disease characteristics, treatments, and...
2.
Venner C, Duggan P, Song K, Reece D, Sharma S, Su J, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):889-901.
PMID: 38971462
In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem...
3.
Bhella S, Wilkin A, Hueniken K, Vijenthira A, Sebag M, Wang P, et al.
Vaccine
. 2024 Jun;
42(24):126074.
PMID: 38944577
Background: Immune response to COVID-19 vaccine is diminished in patients with hematologic malignancy. There is limited data regarding response to vaccine doses in these patients. Purpose: To quantify the humoral...
4.
Kaedbey R, Reece D, Venner C, McCurdy A, Su J, Chu M, et al.
EJHaem
. 2024 Jun;
5(3):474-484.
PMID: 38895063
Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study aims to evaluate the outcomes in newly...
5.
Cote J, LeBlanc R, Mian H, Chu M, McCurdy A, Masih-Khan E, et al.
Blood Cancer J
. 2023 Sep;
13(1):137.
PMID: 37669949
Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we...
6.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda V, Su J, Masih-Khan E, et al.
Blood Cancer J
. 2023 Aug;
13(1):129.
PMID: 37635183
No abstract available.
7.
Bridges S, Fowler S, McLaughlin L, Robichaud M, Ridgway B, Reece D, et al.
Res Involv Engagem
. 2023 Jul;
9(1):60.
PMID: 37516883
Background: Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma. However, there has been limited investigation...
8.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda V, Su J, Masih-Khan E, et al.
Blood Cancer J
. 2023 Jul;
13(1):111.
PMID: 37474492
While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and characteristics of patients not receiving subsequent therapy is useful for...
9.
Proctor C, Reiman A, Best L
J Cancer Surviv
. 2023 Mar;
18(1):196-206.
PMID: 36964294
Purpose: Our purpose was to examine the associations between the pillars of psychological flexibility (valued action, behavioural awareness, openness to experience) and aspects of quality of working life after a...
10.
McCurdy A, Louzada M, Venner C, Visram A, Masih-Khan E, Kardjadj M, et al.
EJHaem
. 2022 Dec;
3(4):1252-1261.
PMID: 36467802
Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated...